How can Europe speed up the adoption of new cancer research advances, strengthen cross-border collaboration and ensure that scientific progress reaches patients sooner? European leading voices from cancer research, healthcare, policy, patient organisations and industry will gather in Stockholm for Momentum 2026. On 14-16 October they to explore how Europe can shorten the path from scientific discovery to clinical practice.
Confirmed speakers include Greg Simon , former Executive Director of the White House Cancer Moonshot Task Force, Joanna Drake , Deputy Director-General at the European Commission's Directorate-General for Research and Innovation, Cary Adams , CEO of the Union for International Cancer Control (UICC)and Elisabete Weiderpass, Director General, International Agency for Research on Cancer (IARC). ( Full list speakers MOMENTUM)
The programme will also feature a panel of leading journalists providing commentary and reflections throughout the conference, including Sarah Neville , Global Health Editor at the Financial Times ; Alexandra Ivanov Hökmark , Associate Editor at Dagens industri ; and Helena Smolak , Pharma Correspondent at Handelsblatt.
Journalists are welcome to attend. Accreditation is free of charge, but advance registration is required. To register, please complete the form here Register | MOMENTUM
The conference Momentum is convened by the Swedish Cancer Society The Swedish Cancer Society | Cancerfonden as the organisation marks 75 years of supporting advances in cancer research and patient care.
--
From the program : Across Europe, world-class cancer research discoveries are being made – yet too often they take too long to reach patients. The gap between research, decision-making, and real-world impact remains one of our greatest missed opportunities. Momentum brings together a carefully curated group of leaders from across sectors: policymakers, healthcare leaders, patient representatives, researchers, civil society, industry and investors - all with a shared ambition: to accelerate Europe’s action on cancer.
"The bottleneck is time. Every year we spend moving a discovery through regulatory, reimbursement, and clinical trial bureaucracies is a year patients don’t have. The next breakthrough won’t come from a single lab – it will come from collapsing the distance between discovery and patient. [...] I want to leave Sweden with at least one conversation that changes how I think about something. Not panels - conversations." ( Greg Simon, Former Executive Director, White House Cancer Moonshot Task Force)
The Swedish Cancer Society | Cancerfonden is an independent, non-profit organisation dedicated to beating cancer. By funding the highest quality research, spreading knowledge about cancer, and influencing decision-making in key areas, we work to ensure that fewer people are affected and more people survive. We have contributed with 18 billion SEK to Swedish cancer research since the start. As a result of progress in research, cancer survival rates have more than doubled in Sweden - today, seven out of ten people diagnosed with cancer survive. We have come far, but there is still more to be done.